AR045177A1 - Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave - Google Patents
Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o graveInfo
- Publication number
- AR045177A1 AR045177A1 ARP040102722A ARP040102722A AR045177A1 AR 045177 A1 AR045177 A1 AR 045177A1 AR P040102722 A ARP040102722 A AR P040102722A AR P040102722 A ARP040102722 A AR P040102722A AR 045177 A1 AR045177 A1 AR 045177A1
- Authority
- AR
- Argentina
- Prior art keywords
- tazarotene
- compound
- prepare
- pharmaceutical composition
- acne
- Prior art date
Links
- 229960000565 tazarotene Drugs 0.000 title abstract 4
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract 2
- -1 TAZAROTENE COMPOUND Chemical class 0.000 title abstract 2
- 206010000496 acne Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 abstract 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960005280 isotretinoin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un compuesto tazaroteno para preparar una composición farmacéutica de utilidad para tratar acné noduloquístico severo o grave en un animal o humano, mediante la administración a dicho humano o animal de una dosis sistémica terapéuticamente efectiva de la composición que comprende dicho compuesto. Preferentemente, la dosis es una dosis oral de tazaroteno de alrededor de 4,5 mg/día. Dicha dosis sistémica terapéuticamente efectiva de tazaroteno es tal que produce, por lo menos, un efecto secundario menor o menos severo que una dosis sistémica de isotretinoina que posee eficacia similar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49114303P | 2003-07-30 | 2003-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045177A1 true AR045177A1 (es) | 2005-10-19 |
Family
ID=34115472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102722A AR045177A1 (es) | 2003-07-30 | 2004-07-30 | Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050026958A1 (es) |
| EP (1) | EP1653941A1 (es) |
| AR (1) | AR045177A1 (es) |
| AU (1) | AU2004261286A1 (es) |
| CA (1) | CA2534005A1 (es) |
| TW (1) | TW200509922A (es) |
| WO (1) | WO2005011667A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060620A1 (en) * | 2005-09-09 | 2007-03-15 | John Sefton | Use of RAR retinoid agonists to increase sperm count and sperm mobility in males |
| EP1971331A2 (en) * | 2005-12-09 | 2008-09-24 | Basilea Pharmaceutica AG | 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4322438A (en) * | 1979-08-06 | 1982-03-30 | United States Of America | Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| US6248354B1 (en) * | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
-
2004
- 2004-07-29 US US10/902,719 patent/US20050026958A1/en not_active Abandoned
- 2004-07-29 WO PCT/US2004/024966 patent/WO2005011667A1/en not_active Ceased
- 2004-07-29 AU AU2004261286A patent/AU2004261286A1/en not_active Abandoned
- 2004-07-29 EP EP04779893A patent/EP1653941A1/en not_active Withdrawn
- 2004-07-29 CA CA002534005A patent/CA2534005A1/en not_active Abandoned
- 2004-07-30 TW TW093122946A patent/TW200509922A/zh unknown
- 2004-07-30 AR ARP040102722A patent/AR045177A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1653941A1 (en) | 2006-05-10 |
| AU2004261286A1 (en) | 2005-02-10 |
| CA2534005A1 (en) | 2005-02-10 |
| TW200509922A (en) | 2005-03-16 |
| WO2005011667A1 (en) | 2005-02-10 |
| US20050026958A1 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
| AR074313A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit | |
| AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR042938A1 (es) | Uso del cci-779 en el tratamiento de la fibrosis hepatica | |
| MX2007000117A (es) | Una composicion de combinacion. | |
| MXPA04001397A (es) | Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina. | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| ES2124983T3 (es) | Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno. | |
| GT200600160A (es) | Tratamiento del dolor | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| CL2004000984A1 (es) | Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica. | |
| AR045177A1 (es) | Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave | |
| CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
| UY30557A1 (es) | Tratamiento y prevencion de la fibrosis intestinal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |